Letrozole 2.5mg Tablets

Letrozole 2.5mg Tablets is a highly potent, non-steroidal aromatase inhibitor (Type II) specifically engineered for the hormonal manipulation of estrogen-dependent conditions. As a third-generation inhibitor, this pharmaceutical agent functions by selectively binding to the heme group of the aromatase enzyme (cytochrome P450 19A1). This enzyme is the rate-limiting step in the biosynthesis of estrogen, responsible for converting adrenal androgens (androstenedione and testosterone) into estrogens (estrone and estradiol) in peripheral tissues. By competitively inhibiting this enzymatic conversion, the medication effectively suppresses plasma estrogen levels by 99% or more in postmenopausal women. This profound reduction “starves” hormone receptor-positive breast cancer cells of the estrogen they require to proliferate, leading to tumor regression or stabilization. Discover how this powerful pharmacological intervention provides the ultimate clinical strategy for long-term disease management, offering effective relief and significantly improving survival outcomes by targeting the molecular fuel of the malignancy.

Indications / Uses of Letrozole 2.5mg Tablets

This product is commonly prescribed for the specialized management of oncological and reproductive conditions:

• Adjuvant Treatment of Early Breast Cancer: It is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. Clinical data confirms that the drug significantly reduces the risk of recurrence compared to tamoxifen.
• Extended Adjuvant Treatment: The therapy is used for the extended adjuvant treatment of early breast cancer in postmenopausal women who have already received 5 years of adjuvant tamoxifen therapy, providing an additional layer of protection.
• Advanced or Metastatic Breast Cancer: Letrozole 2.5mg Tablets is a first-line treatment for postmenopausal women with hormone receptor-positive or unknown, locally advanced, or metastatic breast cancer. It is also used as second-line therapy after disease progression on anti-estrogen therapy.
• Ovulation Induction (Off-Label): In reproductive medicine, the medication is frequently prescribed to induce ovulation in women with anovulatory infertility, such as those with Polycystic Ovary Syndrome (PCOS). By lowering estrogen, it triggers the pituitary gland to release more Follicle Stimulating Hormone (FSH), promoting follicle development.

Key Features

• High Specificity and Potency: The primary feature of the tablet is its ability to achieve near-total suppression of estrogen without affecting the synthesis of other necessary steroid hormones like cortisol or aldosterone.
• Superior Oral Bioavailability: The active ingredient is rapidly and completely absorbed after oral administration, ensuring that the 2.5mg dose delivers consistent therapeutic plasma levels regardless of food intake.
• Standardized Dosage: The 2.5mg strength is the globally established therapeutic dose, optimized to balance maximum estrogen suppression with a manageable side effect profile.
• Proven Survival Benefit: Extensive clinical trials have demonstrated that this treatment improves disease-free survival rates in the adjuvant setting, making it a cornerstone of modern oncology.
• Lack of Intrinsic Hormonal Activity: Unlike tamoxifen, this aromatase inhibitor has no estrogenic activity, eliminating the risk of endometrial proliferation or uterine cancer associated with SERMs.

Storage for Letrozole 2.5mg Tablets

To preserve the pharmacological stability and ultimate potency of the active ingredients, the medication should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Deviations are permitted between 15°C and 30°C (59°F to 86°F). It is vital to keep the units in their original, moisture-resistant manufacturer packaging or blister packs until the moment of administration. Exposure to high humidity or direct sunlight can compromise the chemical integrity of the tablet matrix. For maximum safety, always store the product in a secure, dry location that is strictly out of the reach and sight of children and pets. Do not dispose of unused medication in wastewater; consult a pharmacist for proper disposal protocols.

Important Note on Letrozole 2.5mg Tablets

The administration of Letrozole 2.5mg Tablets is primarily intended for postmenopausal women. The medication is generally contraindicated in premenopausal women unless utilized in specific fertility protocols or combined with ovarian suppression. One of the most critical long-term risks associated with this therapy is the reduction of bone mineral density (BMD), which can lead to osteoporosis and an increased risk of bone fractures. Patients should undergo regular bone density scanning (DEXA scans) and may require calcium and Vitamin D supplementation or bisphosphonate therapy.

Cholesterol levels should also be monitored, as the drug can lead to hypercholesterolemia. Common side effects include hot flashes (“hot flushes”), night sweats, fatigue, and arthralgia (joint pain/stiffness), which is a frequent cause of discontinuation; patients should be encouraged to stay active to manage joint symptoms. Dizziness and fatigue may impair the ability to drive or operate machinery. This medication is classified as Pregnancy Category X; it can cause fetal harm and must not be taken by women who are pregnant or may become pregnant. If used for fertility treatments, strict timing and pregnancy testing are required to ensure the drug is cleared from the system before conception. By adhering to these professional guidelines and monitoring schedules, patients can maximize the life-extending benefits of this treatment.